Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone

Bone ◽  
2007 ◽  
Vol 40 (2) ◽  
pp. 457-463 ◽  
Author(s):  
G. Martini ◽  
L. Gennari ◽  
D. Merlotti ◽  
S. Salvadori ◽  
M.B. Franci ◽  
...  
Keyword(s):  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Bisphosphonate Treatment ◽  
Before And After ◽  
Intravenous Bisphosphonate

scholarly journals Randomized trial of intensive bisphosphonate treatment versus symptomatic management in paget's disease of bone

2009 ◽  
Vol 25 (1) ◽  
pp. 20-31 ◽  
Author(s):  
Anne L Langston ◽  
Marion K Campbell ◽  
William D Fraser ◽  
Graeme S MacLennan ◽  
Peter L Selby ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Bisphosphonate Treatment ◽  
Symptomatic Management

scholarly journals Paget’s disease of bone, biphosphonates and jaw osteonecrosis: a case report

NEMESIS ◽  
2019 ◽  
Vol 4 (1) ◽  
pp. 15
Author(s):  
Michele Magremanne ◽  
Anne Grysolle ◽  
Hervé Reychler
Keyword(s):  
Case Report ◽  
Paget’S Disease ◽  
Rare Event ◽  
Rare Condition ◽  
Osteonecrosis Of The Jaw ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Bisphosphonate Treatment ◽  
Oncologic Patients

Objective: Paget’s disease of bone is characterized by a focal increase in bone resorption and accelerated bone formation leading to a weaker and disorganised bone. Bisphosphonates (BPs) have been the treatment of choice of Paget’s disease since the 1990s. Medication related osteonecrosis of the jaw (MRONJ) is a rare event in non oncologic patients. We describe a rare case of  Paget’s disease involving the maxilla with osteonecrosis in a context of bisphosphonate treatment.   Case report: an 87-year-old woman presented with 4 episodes of bone necrosis in 15 years. In this case report there is a clear chronologic association between the occurrence of MRONJ and the administration of iv BP for Paget’s disease. Maxillofacial involvement of Paget’s disease occurs in less than 15% of cases. There is a lack of information in the literature about the association of MRONJ and Paget’s disease. Even if osteonecrosis of the jaw could be a consequence of the disease, in this case, it is more in relation to the BP treatment.   Conclusions: Although MRONJ might be considered a rare condition in Paget’s disease, patients prior to starting antiresorptive therapy and in particular iv BPs should have a complete dental examination and panoramic X-Ray.   Nemesis relevance: side effect of bisphosphonate treatment  

Pharmacogenomics of bisphosphonate treatment in Paget's disease of bone: retrospective and prospective analysis

2014 ◽  
Author(s):  
Daniela Merlotti ◽  
Fernando Gianfrancesco ◽  
Domenico Rendina ◽  
Riccardo Muscariello ◽  
Teresa Esposito ◽  
...  
Keyword(s):  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Prospective Analysis ◽  
Paget's Disease Of Bone ◽  
Bisphosphonate Treatment

scholarly journals Comparison of Different Intravenous Bisphosphonate Regimens for Paget's Disease of Bone

2007 ◽  
Vol 22 (10) ◽  
pp. 1510-1517 ◽  
Author(s):  
Daniela Merlotti ◽  
Luigi Gennari ◽  
Giuseppe Martini ◽  
Fabrizio Valleggi ◽  
Vincenzo De Paola ◽  
...  
Keyword(s):  
Paget’S Disease ◽  
Paget's Disease ◽  
Paget’S Disease Of Bone ◽  
Paget's Disease Of Bone ◽  
Intravenous Bisphosphonate
Sign in / Sign up

Export Citation Format

Share Document